On October 14, 2026, international lymphoma panels emphasized the definitive clinical value of Columvi® (Glofitamab-gxbm 2.5 mg and 10 mg concentrate for solution for infusion) developed by Roche for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Columvi features a novel 2:1 molecular configuration (two CD20-binding Fab regions and one CD3-binding Fab region), creating exceptionally high avidity for malignant B-cells and delivering high complete remission rates over a fixed 12-cycle treatment duration.

Through Critical Kare Pharma, genuine Roche packs of Columvi Glofitamab Infusion Vials are provided to oncology clinics and named patients globally under verified 2°C–8°C custody.

The NP30179 Clinical Benchmark

• Deep Complete Remissions: 52% overall response rate with a 39% complete response rate in patients with relapsed/refractory DLBCL who failed a median of three prior therapies.
• Durable Off-Treatment Remissions: Over 78% of complete responders remained in remission 18 months post-completion of the fixed 12-cycle regimen.
• Obinutuzumab Pre-Treatment: Single 1000 mg dose of obinutuzumab on Day 1 of Cycle 1 depletes peripheral B-cells, followed by step-up glofitamab (2.5 mg Day 8, 10 mg Day 15, 30 mg Cycle 2 Day 1).

Global Access via Critical Kare Pharma

Coordinated under US FDA Personal Importation Policy (PIP), UK Named-Patient Import, and Brazilian ANVISA authorizations.